TrovaGene (TROV 4.46) initiated with a Buy at Maxim Group; Target $12. Firm notes the partnership with the leading academic center in pancreatic cancer should help further validate the utility of Trovagene's Trovera KRAS test as a non-invasive diagnostic alternative to identify and monitor pancreatic cancer (mutations), thus enabling diagnostic guided therapy, which potentially offers benefits to patients. They assume 565,000 stage IV cancer patients who could benefit from diagnostic guided therapy (at five tests per patient and $1000 per test) and a 10% potential market share, equating to a multi-billion dollar opportunity. As such, they believe their out-year assumed sales of $500M (2025) are possible as the cancer paradigm changes.
Thanks for your reply. I looked at ARWR and they have just one drug in their pipeline in Phase 2. The others are mostly pre-clinical. My inclination is to believe that GILD would be looking for a larger player but again, appreciate your heads up.
At the conference...
CSO Norbert Bischofberger states that he is "spending about 30% of my time looking at external opportunities."
Co does not believe that they have a need to expand its candidates in NASH.
" Biggest need is in oncology." Thinks that to fully build out the oncology program they need a few more items in the pipeline.
So what companies are the possible buy -outs ? I know INCY is one such company. Anyone have other thoughts?
A block trade is an order or trade submitted for sale OR purchase of a large quantity of securities. A block trade involves a significantly large number of shares or bonds being traded at an arranged price between parties, outside of the open markets, in order to lessen the impact of such a large trade hitting the tape.
No idea if someone is unloading. I would be acquiring.